Introduction: Anti-vascular endothelial growth factor (VEGF) injections are a crucial treatment for neovascular age-related macular degeneration (nvAMD). However, each injection carries the risk of complications, including macular hole (MH) formation. A comprehensive literature search of the PubMed, Embase, and Google Scholar databases identified studies reporting MH formation after anti-VEGF injections for nvAMD. Demographic characteristics included age, sex and affected eye. The presence of intraretinal fluid, subretinal fluid (SRF), pigment epithelial detachment (PED), posterior vitreous detachment, epiretinal membrane, vitreomacular adhesion (VMA), vitreomacular traction (VMT), and retinal pigment epithelial (RPE) tears was recorded. This review includes 15 articles, encompassing 50 eyes. Median patient age was 76.0 years, and 54% were female. Prior to MH formation, SRF and PED were present in 68% of eyes. VMA or VMT was observed in 36% of eyes and the median number of injections before MH development was 3, with a median time to diagnosis of 60 days. While anti-VEGF is an essential therapy, clinicians must be aware of the risk of MH. Predisposing factors including PEDs, VMT, and significant intra- or subretinal fluid, should be considered. Further research is needed to fully understand the mechanisms and explore preventative strategies.
Rhegmatogenous retinal detachments (RRDs) with inferior retinal breaks (IRBs) pose significant surgical challenges, lacking a universally accepted treatment standard. Heavy silicone oils (HSOs), specifically Densiron® 68 and Densiron XTRA, have emerged as promising endotamponade agents because of their specific gravity, which is greater than that of water, allowing effective tamponade in the inferior retina. Unlike earlier HSO formulations, these newer variants show reduced rates of intraocular inflammation while maintaining favorable anatomical outcomes, even when compared with concomitant scleral buckle (SB) use; however, their usage remains limited, particularly in the U.S. This systematic review assessed clinical indications, anatomical reattachment rates, and intraocular inflammation linked to Densiron 68 and Densiron XTRA. A comprehensive search of Ovid MEDLINE, EMBASE, and Cochrane CENTRAL identified 616 references, of which 22 studies involving 970 eyes met the inclusion criteria. Pooled analyses revealed a 16.7% rate of oil dispersion and emulsification, 13.0% incidence of intraocular inflammation, and 7.1% occurrence of oil migration into the anterior chamber. Notably, anatomical retinal reattachment following endotamponade removal was achieved in 80.1% of cases. These findings underscore the efficacy of Densiron 68 and Densiron XTRA in managing complex primary and secondary RRDs, offering a potentially viable solution with lower complication rates than prior HSOs. Their demonstrated success in achieving high anatomical reattachment rates positions them as promising tools in advancing RRD treatment.

